MODERN MANAGEMENT OF HER2-POSITIVE GASTRIC CANCER: CLINICAL INSIGHTS AND EVIDENCE FROM TRIALS
DOI:
https://doi.org/10.31435/ijitss.3(47).2025.3784Keywords:
Gastric Cancer, HER2, Trastuzumab, Targeted Therapy, Chemotherapy, Trastuzumab Deruxtecan, Zanidatamab, KN026Abstract
Introduction: Gastric cancer (GC) remains a major global health issue, ranking among the leading causes of cancer-related deaths worldwide. Despite improvements in diagnostic methods, many patients are still diagnosed at an advanced stage. The discovery of HER2 overexpression in approximately 15–20% of GC cases introduced targeted therapy into clinical practice. The ToGA trial established trastuzumab combined with chemotherapy as the first-line treatment for HER2-positive advanced GC, significantly improving survival.
Aim of the study: This review summarizes current knowledge about the epidemiology, clinical staging, and treatment strategies for advanced gastric cancer, with particular focus on HER2-positive tumors. It also outlines the evolution of HER2-targeted therapies and discusses novel agents and clinical trials that may shape future management.
Material and methods: The review was based on data collected from PubMed and Google Scholar using key terms: gastric cancer, HER2-positive, chemotherapy, targeted therapy, immunotherapy, clinical trials, ToGA, T-DXd, ZW25, KN026.
Conclusion: GC is a complex and heterogeneous disease that requires accurate staging and individualized treatment strategies. While traditional chemotherapy remains the foundation of care, the incorporation of targeted therapies and immune checkpoint inhibitors has changed the treatment landscape. HER2 remains a critical biomarker, with newer agents such as trastuzumab deruxtecan, zanidatamab, and KN026 showing promising results. Continued molecular profiling and participation in clinical trials are essential for improving outcomes in HER2-positive GC patients.
References
Luo D, Liu Y, Lu Z, Huang L. Targeted therapy and immunotherapy for gastric cancer: rational strategies, novel advancements, challenges, and future perspectives. Mol Med. 2025 Feb 8;31(1):52. doi:10.1186/s10020-025-01075-y. PMID: 39923010
Lordick F, Carneiro F, Cascinu S, Fleitas T, Haustermans K, Piessen G, Vogel A, Smyth EC; ESMO Guidelines Committee. Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022 Oct;33(10):1005–1020. doi:10.1016/j.annonc.2022.07.004. PMID: 35914639
Ajani JA, D’Amico TA, Almhanna K, et al. Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022;20(2):167–192. PMID: 35130502
Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687–697. doi:10.1016/S0140-6736(10)61121-X. PMID: 20728210
Shitara K, Bang YJ, Iwasa S, et al. Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer. N Engl J Med. 2020;382(25):2419–2430. doi:10.1056/NEJMoa2004413. PMID: 32469182
López-Sala P, et al. Gastric adenocarcinoma: A review of the TNM classification system. Radiologia. 2022;64(2):123–134. doi:10.1016/j.rxeng.2022.01.003. PMID: 36842787
Kim TH, et al. Revisiting the 8th AJCC system for gastric cancer: current issues and future perspectives. J Gastric Cancer. 2022;22(1):1–10. doi:10.5230/jgc.2022.22.e2. PMID: 35386808
Giandola T, Rinzivillo M, Panzuto F, Capurso G. Imaging in gastric cancer: current practice and future perspectives. Diagnostics (Basel). 2023;13(7):1276. doi:10.3390/diagnostics13071276. PMID: 37046494
https://www.cancer.gov/types/stomach/stages
Shitara K, Matsuo K, Mizota A, Kondo C, Nomura M, Takahari D, Yokota T, Ura T, Ito S, Sawaki A, Tajika M, Kawai H, Muro K. Association of fluoropyrimidines, platinum agents, taxanes, and irinotecan in any line of chemotherapy with survival in patients with advanced gastric cancer. Gastric Cancer. 2011 Jun;14(2):155-60. doi: 10.1007/s10120-011-0019-3. Epub 2011 Feb 23. PMID: 21340668.
Kang BW, Kim JG, Kwon OK, Chung HY, Yu W. Non-platinum-based chemotherapy for treatment of advanced gastric cancer: 5-fluorouracil, taxanes, and irinotecan. World J Gastroenterol. 2014 May 14;20(18):5396-402. doi: 10.3748/wjg.v20.i18.5396. PMID: 24833869; PMCID: PMC4017054.
Hall PS, Swinson D, Cairns DA, Waters JS, Petty R, Allmark C, Ruddock S, Falk S, Wadsley J, Roy R, Tillett T, Nicoll J, Cummins S, Mano J, Grumett S, Stokes Z, Kamposioras KV, Chatterjee A, Garcia A, Waddell T, Guptal K, Maisey N, Khan M, Dent J, Lord S, Crossley A, Katona E, Marshall H, Grabsch HI, Velikova G, Ow PL, Handforth C, Howard H, Seymour MT; GO2 Trial Investigators. Efficacy of Reduced-Intensity Chemotherapy With Oxaliplatin and Capecitabine on Quality of Life and Cancer Control Among Older and Frail Patients With Advanced Gastroesophageal Cancer: The GO2 Phase 3 Randomized Clinical Trial. JAMA Oncol. 2021 Jun 1;7(6):869-877. doi: 10.1001/jamaoncol.2021.0848. Erratum in: JAMA Oncol. 2021 Aug 1;7(8):1249. doi: 10.1001/jamaoncol.2021.2796. PMID: 33983395; PMCID: PMC8120440.
Shitara K, Takashima A, Fujitani K, Koeda K, Hara H, Nakayama N, Hironaka S, Nishikawa K, Makari Y, Amagai K, Ueda S, Yoshida K, Shimodaira H, Nishina T, Tsuda M, Kurokawa Y, Tamura T, Sasaki Y, Morita S, Koizumi W. Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trial. Lancet Gastroenterol Hepatol. 2017 Apr;2(4):277-287. doi: 10.1016/S2468-1253(16)30219-9. Epub 2017 Jan 19. PMID: 28404157.
Shitara K, Doi T, Dvorkin M, Mansoor W, Arkenau HT, Prokharau A, Alsina M, Ghidini M, Faustino C, Gorbunova V, Zhavrid E, Nishikawa K, Hosokawa A, Yalçın Ş, Fujitani K, Beretta GD, Cutsem EV, Winkler RE, Makris L, Ilson DH, Tabernero J. Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2018 Nov;19(11):1437-1448. doi: 10.1016/S1470-2045(18)30739-3. Epub 2018 Oct 21. Erratum in: Lancet Oncol. 2018 Dec;19(12):e668. doi: 10.1016/S1470-2045(18)30843-X. PMID: 30355453.
Zeng Z, Zhu Q. Progress and prospects of biomarker-based targeted therapy and immune checkpoint inhibitors in advanced gastric cancer. Front Oncol. 2024 Jun 14;14:1382183. doi: 10.3389/fonc.2024.1382183. PMID: 38947886; PMCID: PMC11211377.
Lei ZN, Teng QX, Tian Q, Chen W, Xie Y, Wu K, Zeng Q, Zeng L, Pan Y, Chen ZS, He Y. Signaling pathways and therapeutic interventions in gastric cancer. Signal Transduct Target Ther. 2022 Oct 8;7(1):358. doi: 10.1038/s41392-022-01190-w. PMID: 36209270; PMCID: PMC9547882.
Moehler M, Oh DY, Kato K, Arkenau T, Tabernero J, Lee KW, Rha SY, Hirano H, Spigel D, Yamaguchi K, Wyrwicz L, Disel U, Pazo-Cid RA, Fornaro L, Xu Y, Sheng T, Yang S, Kadva A, Cruz-Correa M, Xu RH. First-Line Tislelizumab Plus Chemotherapy for Advanced Gastric Cancer with Programmed Death-Ligand 1 Expression ≥ 1%: A Retrospective Analysis of RATIONALE-305. Adv Ther. 2025 May;42(5):2248-2268. doi: 10.1007/s12325-025-03133-7. Epub 2025 Mar 13. PMID: 40075025; PMCID: PMC12006226.
Zhang H, Wang Y, Wang Y, Wu D, Lin E, Xia Q. Intratumoral and intertumoral heterogeneity of HER2 immunohistochemical expression in gastric cancer. Pathol Res Pract. 2020 Nov;216(11):153229. doi: 10.1016/j.prp.2020.153229. Epub 2020 Sep 21. PMID: 33010699.
Lee HE, Park KU, Yoo SB, Nam SK, Park DJ, Kim HH, Lee HS. Clinical significance of intratumoral HER2 heterogeneity in gastric cancer. Eur J Cancer. 2013 Apr;49(6):1448-57. doi: 10.1016/j.ejca.2012.10.018. Epub 2012 Nov 9. PMID: 23146959.
Zhou Y, Wang X, Chen Y. Margetuximab: An active alternative for later-line therapy in patients with HER2-positive advanced breast cancer. MedComm (2020). 2023 Jul 4;4(4):e322. doi: 10.1002/mco2.322. PMID: 37409110; PMCID: PMC10318489.
Elimova E, Ajani J, Burris H, Denlinger CS, Iqbal S, Kang YK, Kim JH, Lee KW, Lin B, Mehta R, Oh DY, Rha SY, Seol YM, Yang L, Ozog MA, Garfin PM, Ku G. Zanidatamab plus chemotherapy as first-line treatment for patients with HER2-positive advanced gastro-oesophageal adenocarcinoma: primary results of a multicentre, single-arm, phase 2 study. Lancet Oncol. 2025 May 30:S1470-2045(25)00287-6. doi: 10.1016/S1470-2045(25)00287-6. Epub ahead of print. PMID: 40473445.
Liu D, Gong J, Li J, Qi C, Niu Z, Liu B, Peng Z, Luo S, Wang X, Wang Y, Zhao R, Chen L, Deng T, Li Z, Chen L, Fang M, Yang H, Lu L, Zhang Y, Kang F, Xu T, Zhang X, Shen L. Efficacy and safety of KN026, a bispecific anti-HER2 antibody, in combination with KN046, an anti-CTLA4/PD-L1 antibody, in patients with advanced HER2-positive nonbreast cancer: a combined analysis of a phase Ib and a phase II study. Signal Transduct Target Ther. 2025 Mar 19;10(1):104. doi: 10.1038/s41392-025-02195-x. PMID: 40108113; PMCID: PMC11923254.
Van Cutsem E, di Bartolomeo M, Smyth E, Chau I, Park H, Siena S, Lonardi S, Wainberg ZA, Ajani J, Chao J, Janjigian Y, Qin A, Singh J, Barlaskar F, Kawaguchi Y, Ku G. Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study. Lancet Oncol. 2023 Jul;24(7):744-756. doi: 10.1016/S1470-2045(23)00215-2. Epub 2023 Jun 14. PMID: 37329891; PMCID: PMC11298287.
Shitara K, Bang YJ, Iwasa S, Sugimoto N, Ryu MH, Sakai D, Chung HC, Kawakami H, Yabusaki H, Lee J, Saito K, Kawaguchi Y, Kamio T, Kojima A, Sugihara M, Yamaguchi K; DESTINY-Gastric01 Investigators. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer. N Engl J Med. 2020 Jun 18;382(25):2419-2430. doi: 10.1056/NEJMoa2004413. Epub 2020 May 29. PMID: 32469182.
Kawakami H, Nakanishi K, Makiyama A, Konishi H, Morita S, Narita Y, Sugimoto N, Minashi K, Imano M, Inamoto R, Kodera Y, Kume H, Yamaguchi K, Hashimoto W, Muro K; EN-DEAVOR Study Group. Real-world effectiveness and safety of trastuzumab-deruxtecan in Japanese patients with HER2-positive advanced gastric cancer (EN-DEAVOR study). Gastric Cancer. 2025 Jan;28(1):51-61. doi: 10.1007/s10120-024-01555-w. Epub 2024 Oct 10. Erratum in: Gastric Cancer. 2025 Jan;28(1):62. doi: 10.1007/s10120-024-01570-x. PMID: 39387986; PMCID: PMC11706843.
Downloads
Published
Issue
Section
License
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
How to Cite
